POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.

Iowa requires health insurance plans to cover metastatic cancer prescription drugs without step therapy

Original title: A bill for an act relating to insurance coverage for prescription drugs used in the treatment of metastatic cancer and associated conditions.

Last action · February 11, 2025: Subcommittee recommends passage.Sponsor: Annette Sweeney

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Would Do

Senate File 197 requires third-party health insurance contracts, policies, and plans in Iowa to provide coverage for prescription drugs used to treat and without imposing s, starting January 1, 2026.

Why it matters

Patients undergoing treatment for advanced cancer will gain direct access to prescribed medications without insurers requiring them to try alternative drugs first, affecting health plan participants across individual, group, and public employee plans.

Who It Would Affect

Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.

Directly affected

Covered persons and policyholders

Policyholders and participants in health plans receive mandated insurance coverage for metastatic cancer prescription drugs without step therapy protocols starting January 1, 2026.

Directly affected

Third-party payment providers and health insurers

Insurers and health maintenance organizations must update their policy offerings and claims processing to provide coverage for qualifying prescription cancer drugs without step therapy.

Directly affected

Health care professionals

Key Facts

  • Insurers providing third-party payment for prescription drugs must cover prescription cancer drugs used for metastatic cancer and associated conditions.
  • Coverage must be provided without imposing a step therapy protocol for qualifying prescription cancer drugs.
  • Qualifying drugs must be used in accordance with medical standards of care, be supported by peer-reviewed evidence-based literature, and be approved by the United States Food and Drug Administration.
  • The requirements apply to individual or group accident and sickness insurance, hospital or medical service contracts, health maintenance organization contracts, and public employee plans.
Show all 7 facts
  • Exempted insurance types include accident-only, specified disease, short-term hospital or medical, dental, vision, Medicare supplement, long-term care, and workers' compensation.
  • The requirements apply to contracts delivered, issued for delivery, continued, or renewed on or after January 1, 2026.
  • The commissioner of insurance may adopt rules pursuant to chapter 17A to administer the section.

Frequently Asked Questions

What types of cancer does this bill cover?
The bill covers , which is cancer that has spread from the primary or original site to tissue, lymph nodes, or other parts of the body (also referred to as advanced cancer or stage 4 cancer), as well as associated symptoms or side effects.
What does 'without step therapy protocol' mean for patients?
It means insurers cannot require patients to try and fail on other, usually cheaper, drugs before approving coverage for the specific prescription cancer drug prescribed by their health care professional.
When do these insurance coverage rules take effect?
The provisions apply to applicable third-party payment provider contracts, policies, or plans delivered, issued for delivery, continued, or renewed in Iowa on or after January 1, 2026.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Currently in committee. The next step in the legislative lifecycle is Floor Vote.

Procedural history

4 actions
  1. Feb 11, 2025Iowa Legislature
    Subcommittee recommends passage.
  2. Feb 10, 2025Senate
    Subcommittee Meeting: 02/11/2025 1:30PM Senate Lounge.
  3. Feb 5, 2025Senate
    Subcommittee: Sweeney, Koelker, and Petersen. S.J. 203 .
  4. Feb 4, 2025SenateIntroduced
    Introduced, referred to Commerce. S.J. 188 .

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Connected Entities

United States food and drug administration
OrganizationUnited States food and drug administration“Approval body for prescription cancer drugs”Map →

Sources

Open source document

www.legis.iowa.gov

Analysis Score

0–100
  • Significance65
    How much this matters to a regular citizen
  • Controversy35
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz40
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record